Advances in biomarkers related to the efficacy of specific immunotherapy / 国际儿科学杂志

ABSTRACT

Allergy specific immunotherapy ( AIT ) was initiated by Leonard Noon in 1911 for the treatment of patients with hay fever. It is recognized as a therapy that changes the natural course of allergic disea-ses through immunoregulatory mechanisms. After more than 100 years of development, its safety and effieacy has been recognized by scholars at home and abroad. At present, AIT was used to treat the patients of AR and AS. In recent years, some scholars have used AIT as a treatment for food allergy and atopic dermatitis, but 40％ of allergic rhinitis and 10％ ～20％ children with asthma are not effective. There are no validated biomark-ers to monitor or predict clinical efficacy, and further explorations are needed.